[JO, Inho 조인호, JO, Inho 조인호, PARK, Yoon Shin 박윤신, JO, Inho 조인호, PARK, Yoon Shin 박윤신, LEE, Sang Hoon 이상훈, JO, Inho 조인호, PARK, Yoon Shin 박윤신, LEE, Sang Hoon 이상훈, HWANG, Ji-Young 황지영, JO, Inho 조인호, PARK, Yoon Shin 박윤신, LEE, Sang Hoon 이상훈, HWANG, Ji-Young 황지영, JUN, Yesl 전예슬, JO, Inho 조인호, PARK, Yoon Shin 박윤신, LEE, Sang Hoon 이상훈, HWANG, Ji-Young 황지영, JUN, Yesl 전예슬, JIN, Yoon Mi 진윤미, JO, Inho 조인호, PARK, Yoon Shin 박윤신, LEE, Sang Hoon 이상훈, HWANG, Ji-Young 황지영, JUN, Yesl 전예슬, JIN, Yoon Mi 진윤미, KIM, Gyung Ah 김경아, JO, Inho 조인호, PARK, Yoon Shin 박윤신, LEE, Sang Hoon 이상훈, HWANG, Ji-Young 황지영, JUN, Yesl 전예슬, JIN, Yoon Mi 진윤미, KIM, Gyung Ah 김경아, KIM, Ha Yeong 김하영, JO, Inho 조인호, PARK, Yoon Shin 박윤신, LEE, Sang Hoon 이상훈, HWANG, Ji-Young 황지영, JUN, Yesl 전예슬, JIN, Yoon Mi 진윤미, KIM, Gyung Ah 김경아, KIM, Ha Yeong 김하영, KIM, Han Su 김한수] 52, Ewhayeodae-gil 03760 서울시 서대문구 이화여대길 52, SeoulSeodaemun-guSeoul 03760;145, Anam-ro 02841 서울시 성북구 안암로 145, SeoulSeongbuk-guSeoul 02841 The present invention relates to: a method for producing a spheroid form of tonsil-derived stem cells, the method enhancing growth and differentiation efficiency of tonsil-derived stem cells; and a method for producing a spheroid form of parathyroid hormones from the same. The method of the present invention for producing a spheroid form of tonsil-derived stem cells cultures the tonsil-derived stem cells in the form of a spheroid to thereby enhance the proliferation rate of the stem cells per se and significantly increase differentiation potency into parathyroid cells. Thereby, the method has a remarkable effect on the growth and differentiation of the tonsil-derived stem cells into parathyroid cells, etc.

[CHANG, Shin Jae 장신재, CHANG, Shin Jae 장신재, LEE, Soo Young 이수영, CHANG, Shin Jae 장신재, LEE, Soo Young 이수영, LIM, Byung Pil 임병필, CHANG, Shin Jae 장신재, LEE, Soo Young 이수영, LIM, Byung Pil 임병필, KIM, Pan Kyeom 김판겸, CHANG, Shin Jae 장신재, LEE, Soo Young 이수영, LIM, Byung Pil 임병필, KIM, Pan Kyeom 김판겸, PARK, Sang Tae 박상태, CHANG, Shin Jae 장신재, LEE, Soo Young 이수영, LIM, Byung Pil 임병필, KIM, Pan Kyeom 김판겸, PARK, Sang Tae 박상태, AHN, Jung Sun 안정선, CHANG, Shin Jae 장신재, LEE, Soo Young 이수영, LIM, Byung Pil 임병필, KIM, Pan Kyeom 김판겸, PARK, Sang Tae 박상태, AHN, Jung Sun 안정선, PARK, Eun Bee 박은비, CHANG, Shin Jae 장신재, LEE, Soo Young 이수영, LIM, Byung Pil 임병필, KIM, Pan Kyeom 김판겸, PARK, Sang Tae 박상태, AHN, Jung Sun 안정선, PARK, Eun Bee 박은비, KEUM, Sun Ju 금선주, CHANG, Shin Jae 장신재, LEE, Soo Young 이수영, LIM, Byung Pil 임병필, KIM, Pan Kyeom 김판겸, PARK, Sang Tae 박상태, AHN, Jung Sun 안정선, PARK, Eun Bee 박은비, KEUM, Sun Ju 금선주, SONG, Man Ki 송만기, CHANG, Shin Jae 장신재, LEE, Soo Young 이수영, LIM, Byung Pil 임병필, KIM, Pan Kyeom 김판겸, PARK, Sang Tae 박상태, AHN, Jung Sun 안정선, PARK, Eun Bee 박은비, KEUM, Sun Ju 금선주, SONG, Man Ki 송만기, CHOI, Jung Ah 최정아] 19, Academy-ro 51, 22014 인천시 연수구 아카데미로 51번길 19, IncheonYeonsu-guIncheon 22014 The present invention relates to an adjuvant composition containing at least one influenza virus neutralizing and binding molecule and a vaccine composition containing the same. The composition containing at least one influenza virus neutralizing and binding molecule of the present invention was confirmed to increase the effects of a vaccine, and thus the composition can be used as an adjuvant, which increases an immune response at the time of vaccine administration, and is very useful in the prevention of diseases caused by viruses.

[SHIN, Young Kee 신영기, SHIN, Young Kee 신영기, PARK, Sang-Ho 박상호, SHIN, Young Kee 신영기, PARK, Sang-Ho 박상호, SONG, Kyoung 송경, SHIN, Young Kee 신영기, PARK, Sang-Ho 박상호, SONG, Kyoung 송경, LEE, Heejung 이희정, SHIN, Young Kee 신영기, PARK, Sang-Ho 박상호, SONG, Kyoung 송경, LEE, Heejung 이희정, GWAK, Eunhye 곽은혜, SHIN, Young Kee 신영기, PARK, Sang-Ho 박상호, SONG, Kyoung 송경, LEE, Heejung 이희정, GWAK, Eunhye 곽은혜, JANG, Eun Jin 장은진, SHIN, Young Kee 신영기, PARK, Sang-Ho 박상호, SONG, Kyoung 송경, LEE, Heejung 이희정, GWAK, Eunhye 곽은혜, JANG, Eun Jin 장은진, JEONG, Seong Hoon 정성훈, SHIN, Young Kee 신영기, PARK, Sang-Ho 박상호, SONG, Kyoung 송경, LEE, Heejung 이희정, GWAK, Eunhye 곽은혜, JANG, Eun Jin 장은진, JEONG, Seong Hoon 정성훈, KIM, Nam Ah 김남아] (Gaepo-dong) Suite 202, Chang-won Bldg, 5, Gaepo-ro 34-gil 06309 서울시 강남구 개포로34길 5, 창원빌딩 202 (개포동), SeoulGangnam-guSeoul 06309 The present invention relates to a stabilized pharmaceutical preparation of R27T comprising a human interferon beta variant (R27T), an acetic acid buffer solution, arginine, mannitol, poloxamer 188, and methionine. The stabilized R27T pharmaceutical preparation according to the present invention comprises an acetic acid buffer solution, arginine, mannitol, poloxamer 188, and methionine, and thereby inhibits formation of an aggregate of an R27T protein and enables long-period storage because of an improvement in thermodynamic and structural stability. Thus, it is expected that the stabilized R27T pharmaceutical preparation will be useful in prevention, improvement and treatment of multiple sclerosis, cancer, autoimmune diseases, viral infectious diseases, HIV infectious diseases, hepatitis C, rheumatoid arthritis, etc.

[LEE BONG YONG, SHIN YOUNG AH, KIM SHIN AE, HAN NA RA, NOH HYEON SEOK, SHIN SOO JEONG, LEE JAE SANG, LEE JAE UN, CHO YOUNG KYOUNG] KR The present invention provides: a novel heterocyclic compound, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a disease related to autotaxin activity, the composition comprising same as an active ingredient. The heterocyclic compound of the present invention exhibits excellent inhibitory activity against autotaxin, and thus can be used in the treatment and prevention of diseases related to autotaxin inhibition, such as fibrotic diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, metabolic diseases, cancer and cancer metastasis, ocular diseases, chronic pruritus in a cholestatic form and other forms, and acute or chronic organ transplant rejection.

[LEE, Bong Yong 이봉용, SHIN, Young Ah 신영아, KIM, Shin Ae 김신애, HAN, Na Ra 한나라, NOH, Hyeon Seok 노현석, SHIN, Soo Jeong 신수정, LEE, Jae Sang 이재상, LEE, Jae Un 이재운, CHO, Young Kyoung 조영경] 17 Pangyo-ro 228beon-gil, Bundang-gu, 13487 경기도 성남시 분당구 판교로228번길 17, Gyeonggi-doSeongnam-si,Gyeonggi-do 13487 The present invention provides: a novel heterocyclic compound, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a disease related to autotaxin activity, the composition comprising same as an active ingredient. The heterocyclic compound of the present invention exhibits excellent inhibitory activity against autotaxin, and thus can be used in the treatment and prevention of diseases related to autotaxin inhibition, such as fibrotic diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, metabolic diseases, cancer and cancer metastasis, ocular diseases, chronic pruritus in a cholestatic form and other forms, and acute or chronic organ transplant rejection.

[LEE BONG YONG, SHIN YOUNG AH, KIM SHIN AE, HAN NA RA, NOH HYEON SEOK, SHIN SOO JEONG, LEE JAE SANG, LEE JAE UN, CHO YOUNG KYOUNG] KR The present invention provides: a novel heterocyclic compound, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a disease related to autotaxin activity, the composition including the same as an active ingredient. The heterocyclic compound of the present invention exhibits excellent inhibitory activity against autotaxin to be used in the treatment and prevention of diseases related to autotaxin inhibition, such as fibrotic diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, metabolic diseases, cancer and cancer metastasis, ocular diseases, chronic pruritus in a cholestatic form and other forms, and acute or chronic organ transplant rejection.

[BO RAM LEE, BONG-YONG LEE, HOE CHUL JUNG, HYE YOUNG HAN, HYN JUNG LEE, HYUN JOO SON, JAE SUN KIN, JE HO RYU, JOON HO SA, JU YOUNG LEE, JUNG A LEE, KEM HO RYU, NAM HO RYU, SHIN AE KIM, SUNG HOON PARK, WON-NO YOUN, YONG HYUK KIN, YOON-JUNG LEE, YOUNG AH SHIN] KR

[RYU, Je Ho, KIM, Shin Ae, RYU, Keun Ho, KIM, Jae Sun, KIM, Nam Ho, HAN, Hye Young, KIM, Yong Hyuk, YOUN, Won-No, LEE, Yoon-Jung, SON, Hyun Joo, LEE, Bong-yong, PARK, Sung Hoon, LEE, Ju Young, LEE, Hyun Jung, JUNG, Hoe Chul, SHIN, Young Ah, LEE, Jung A, LEE, Bo Ram, SA, Joon Ho] 600, Jeongja-dong, Jangan-gu, Suwon-si, Gyeonggi-do 440-300;#101-506, KCC Apt., 1153, Sadang-dong Dongjak-gu Seoul 156-090;#101, 572-3 bunji, Cheoncheon-dong Jangan-gu, Suwon-si Gyeonggi-do 440-330;#122-2001, Gwanak Dreamtown Apt. Seonghyeon-dong, Gwanak-gu Seoul 151-770;#15/5, 1146-3, Seryu 2-dong, Gwonseon-gu, Suwon-si Gyeonggi-do 441-112;#302-1403, Sinbongmaeul Xi 3 Cha Apt. Sinbong-dong, Suji-gu, Yongin-si Gyeonggi-do 448-706;#104-1202, Ssangyong Apt., Seongsu 1-ga 2 dong, Seongdong-gu Seoul 133-756;#301, 103-14, Yuljeon-dong, Jangan-gu Suwon-si Gyeonggi-do 440-320;#1304, Cheongam Doosan Weve Apt. Sillimbon-dong, Gwanak-gu Seoul 151-711;#601-203, Gahyeon Shinhan Apt., 334 Gugal-dong, Yongin-si, Giheung-gu Gyeonggi-do 446-951;#504, Jamwon Ivy, 34-1, Jamwon-dong Seocho-gu Seoul 137-030;#201-2103, Bangbae Raemiantower.,485-3 Bangbae-dong, Seocho-gu Seoul 137-060;#201, 191-17, Eungbong-dong, Seongdong-gu Seoul 133-080;#172-1604, Ggotmebeodeul Maeul Kolon Apt., 730bunji, Hwaseo-dong, Paldal-gu, Suwon-si Gyeonggi-do 442-150;#109-1102, Doosan Apt., Hawolgok 4-dong Seongbuk-gu Seoul 136-130;#1006-1209, Kkachi Maeul Apt., Suseo-dong, Gangnam-gu Seoul 135-520;#113-103, Samsung Raemian 1-Cha Apt. Mabuk-dong, Giheung-gu, Yongin- si Gyeonggi-do 446-557;Hanjin Rosehill Apt., Ojeon-dong, Uiwang-si Gyeonggi-do 437-756;#103-1801, Banpoxi Apt., 20-43, Banpo -dong, Seocho-gu Seoul 137-040;#303, 222-15, Pungnap 1-dong, Songpa-gu Seoul 138-041 Provided are picolinamide and pyrimidine-4-carboxamide compounds, a method for preparing the same, a pharmaceutical composition containing the same, and a medical use using the compound as an agent for preventing, regulating, and treating diseases related to regulation of glucocorticoids by using selective inhibitory activity of the compound for an 11β-HSD1 enzyme. The picolinamide and pyrimidine-4-carboxamide compounds of the present invention are selective inhibitors of human-derived 11β-HSD1 enzymes, and are useful in an agent for preventing, regulating, and treating diseases related to glucocorticoid regulation in which human- derived 11β-HSD1 enzymes are involved, for example, metabolic syndromes such as, type 1 and type 2 diabetes, diabetes later complications, latent autoimmune diabetes adult (LAD A), insulin tolerance syndromes, obesity, impaired glucose tolerane (IGT), impaired fasting glucose (IFG), damaged glucose tolerance, dyslipidemia, atherosclerosis, hypertension, etc.

[RYU JE HO, KIM SHIN AE, RYU KEUN HO, KIM JAE SUN, KIM NAM HO, HAN HYE YOUNG, KIM YONG HYUK, YOUN WON-NO, LEE YOON-JUNG, SON HYUN JOO, LEE BONG-YONG, PARK SUNG HOON, LEE JU YOUNG, LEE HYUN JUNG, JUNG HOE CHUL, SHIN YOUNG AH, LEE JUNG A, LEE BO RAM, SA JOON HO] KR

[CHOI YOUN WOONG, MIN BYUNG GU, HA DAE CHUL, CHO SANG MIN, SONG HEE YONG, PARK HEE CHAN, KWAK SHIN YOUNG, LEE SUNG NEUNG, KWON IN HO, KIM AH YOUNG, KANG JUN HYEOK, PARK JIN AH] KR The present invention relates to a complex agent containing clopidogrel and aspirin, and more specifically, to a complex agent including a capsule containing granules obtained by coating a clopidogrel layer with a rapid release-preventing layer and aspirin granules obtained by coating an aspirin layer with an enteric layer. The present invention can fundamentally block a eutectic phenomenon by blocking the physical contact between the clopidogrel and the aspirin, and thus can prevent changes in the amount, elution properties, and bioequivalence of the agent in the short term and ensure the stability of the agent in the long term. Furthermore, the present invention can prevent the damage to the stomach wall by coating the aspirin with the enteric layer. In addition, the present invention can minimize the production of clopidogrel related substances without the change in the clopidogrel elution amount by containing a moisture-proof coating substrate in order to improve the stability of clopidogrel and its salts sensitive to moisture.